Researchers Submit Patent Application, "Intestinal Mononuclear Phagocytes As Prognostic Biomarker For Crohn'S Disease", for Approval (USPTO 20240425923).

Researchers Gonsky and Targan have submitted a patent application for a method to stratify intestinal mononuclear phagocytes (MNP) expression profiles in individuals with inflammatory bowel disease (IBD), specifically Crohn's Disease (CD). The method aims to identify molecular pathways underlying MNP pathophysiology in treatment-resistant CD patients, with potential implications for personalized treatment strategies. The patent application outlines a detailed process involving gene expression analysis from biological samples to determine CD subtype status and guide treatment decisions based on the identified MNP transcriptomic signatures. [Extracted from the article]